The patient underwent initial treatment for an abdominal aortic aneurysm (aaa) on (b)(6) 2020, which involved the implantation of an afx2 bifurcated stent graft and an afx vela suprarenal.On (b)(6) 2024, it was reported that the patient has developed an endoleak type iiib attributed to a fracture in the afx2 bifurcated stent.A computed tomography (ct) scan revealed that the stent is in contact with the edge of the aneurysm sac, posing a significant risk of rupture.Although the patient's current condition is stable, urgent intervention is necessary to mitigate potential complications.The patient's re-intervention is pending.
|
The reported adverse event/incident was investigated in alignment with endologix operating procedures and work instructions.Where possible, it is endologix's practice to make at least three good-faith efforts to retrieve a reported adverse event/incident-related device as well as medical records and medical imaging.An evaluation of the manufacturing record was completed.A review of the part number/lot number combination needed for device identification shows the device to have been properly manufactured and released in accordance with the device master record.The review confirms there were no manufacturing or processing non-conformities identified that would contribute to the reported adverse event/incident.A clinical evaluation of the adverse event/incident was completed.An examination of medical records and/or medical imaging received by endologix shows the type iiib endoleak with stent fracture at the bifurcation of the main body complaint is confirmed.This is consistent with the reported adverse event/incident.Procedure-related harms, device, user, procedure, or anatomy-relatedness of this complaint could not be determined with the medical records available for review.The final patient status remains unknown.The final patient status was not made available to endologix.No additional investigation of this reported adverse event/incident is planned.However, should additional information relevant to the investigation outcome become available, a follow-up report will be submitted.Endologix will continue to monitor this and similar adverse events/incidents.Device iteration is afx2.Corrections: g3: awareness date has been updated h6: investigation finding codes: remove code 3233 h6: investigation conclusion codes: remove code 11.
|